Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 77,829,584
  • Shares Outstanding, K 109,890
  • Annual Sales, $ 13,117 M
  • Annual Income, $ 3,954 M
  • EBIT $ 3,973 M
  • EBITDA $ 4,394 M
  • 60-Month Beta 0.08
  • Price/Sales 5.99
  • Price/Cash Flow 16.52
  • Price/Book 2.68

Options Overview Details

View History
  • Implied Volatility 35.50% ( -5.08%)
  • Historical Volatility 25.41%
  • IV Percentile 96%
  • IV Rank 78.05%
  • IV High 40.58% on 12/19/24
  • IV Low 17.43% on 06/12/24
  • Put/Call Vol Ratio 2.16
  • Today's Volume 1,923
  • Volume Avg (30-Day) 1,822
  • Put/Call OI Ratio 0.83
  • Today's Open Interest 43,497
  • Open Int (30-Day) 41,283

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 26 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 9.84
  • Number of Estimates 9
  • High Estimate 11.62
  • Low Estimate 8.67
  • Prior Year 10.18
  • Growth Rate Est. (year over year) -3.34%

Price Performance

See More
Period Period Low Period High Performance
1-Month
693.00 +1.28%
on 12/19/24
800.99 -12.38%
on 12/09/24
-41.50 (-5.58%)
since 11/20/24
3-Month
693.00 +1.28%
on 12/19/24
1,154.56 -39.21%
on 09/23/24
-443.18 (-38.70%)
since 09/20/24
52-Week
693.00 +1.28%
on 12/19/24
1,211.20 -42.05%
on 08/27/24
-139.94 (-16.62%)
since 12/20/23

Most Recent Stories

More News
Regeneron Pharmaceuticals Reports Positive Phase 2 Results for Antithrombotic Antibodies REGN7508 and REGN9933 Targeting Factor XI

Regeneron reveals positive Phase 2 results for two Factor XI monoclonal antibodies, targeting thrombosis with favorable safety profiles.Quiver AI SummaryRegeneron Pharmaceuticals has announced positive...

REGN : 701.85 (-0.90%)
Should You Scoop Up This 'Strong Buy' Biotech Before December 23?

Does this top-rated biotech stock deserve a spot in investors' portfolios before its Russell 2000 inclusion?

UPB : 16.21 (-2.41%)
REGN : 701.85 (-0.90%)
AMGN : 263.38 (+0.84%)
Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results

REGN : 701.85 (-0.90%)
Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

REGN : 701.85 (-0.90%)
EYLEA HD® (aflibercept) Injection 8 mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision with Extended Dosing Intervals in Patients with Macular Edema following Retinal Vein Occlusion

REGN : 701.85 (-0.90%)
Regeneron Pharmaceuticals, Inc. Achieves Continued Recognition in Dow Jones Sustainability Indices for 2024

Regeneron Pharmaceuticals announced its sixth inclusion in the Dow Jones Sustainability World Index, reflecting strong corporate responsibility and governance.Quiver AI SummaryRegeneron Pharmaceuticals...

REGN : 701.85 (-0.90%)
Regeneron Named to Dow Jones Sustainability World Index for Sixth Consecutive Year

REGN : 701.85 (-0.90%)
Roche Gets Approval for Vabysmo PFS in EU for Three Retinal Diseases

Roche RHHBY announced that the European Medicines Agency has approved a prefilled syringe (PFS) of the ophthalmology drug Vabysmo (faricimab).The regulatory body approved Vabysmo PFS for use in the treatment...

GILD : 92.57 (+1.62%)
REGN : 701.85 (-0.90%)
RHHBY : 34.5000 (+0.76%)
BMY : 57.33 (+1.83%)
Regeneron Down 15.5% Year to Date: How to Play the Stock?

Shares of Regeneron Pharmaceuticals, Inc. REGN have dropped 15.5% in the year so far compared with the industry’s decline of 6.3%.The stock has underperformed the sector and the S&P 500 Index during...

BAYRY : 4.9100 (-0.41%)
REGN : 701.85 (-0.90%)
RHHBY : 34.5000 (+0.76%)
SNY : 47.71 (+0.44%)
Regeneron Pharmaceuticals Reports Promising Clinical Results for Odronextamab in Treating Various Forms of B-Cell Non-Hodgkin Lymphoma at ASH 2024

Odronextamab shows promise in treating various B-cell lymphomas, with notable efficacy and safety results across multiple trials.Quiver AI SummaryRegeneron Pharmaceuticals announced promising results from...

REGN : 701.85 (-0.90%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also...

See More

Key Turning Points

3rd Resistance Point 729.48
2nd Resistance Point 723.54
1st Resistance Point 712.70
Last Price 701.85
1st Support Level 695.92
2nd Support Level 689.98
3rd Support Level 679.14

See More

52-Week High 1,211.20
Fibonacci 61.8% 1,013.25
Fibonacci 50% 952.10
Fibonacci 38.2% 890.95
Last Price 701.85
52-Week Low 693.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar